An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
ALX has a Chinese challenger
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
TROP2 remains hot
Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.
